Literature DB >> 2792173

Plasma and urinary excretion kinetics of oral baclofen in healthy subjects.

E W Wuis1, M J Dirks, E F Termond, T B Vree, E Van der Kleijn.   

Abstract

Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2792173     DOI: 10.1007/bf00558228

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Creatinine as a marker of glomerular filtration rate.

Authors:  J F Wetzels; F T Huysmans; R A Koene
Journal:  Neth J Med       Date:  1988-10       Impact factor: 1.422

2.  Periodic sharp waves in baclofen-induced encephalopathy.

Authors:  J T Hormes; E E Benarroch; M Rodriguez; D W Klass
Journal:  Arch Neurol       Date:  1988-07

3.  The chemistry and kinetics of Lioresal.

Authors:  J W Faigle; H Keberle
Journal:  Postgrad Med J       Date:  1972-10       Impact factor: 2.401

4.  Quantification of baclofen and its fluoro analogue in plasma and urine after fluorescent derivatisation with benoxaprofen chloride and thin-layer chromatographic separation.

Authors:  D Krauss; H Spahn; E Mutschler
Journal:  Arzneimittelforschung       Date:  1988-10

Review 5.  Drug therapy: spasticity (second of two parts).

Authors:  R R Young; P J Delwaide
Journal:  N Engl J Med       Date:  1981-01-08       Impact factor: 91.245

6.  Enantiospecific high-performance liquid chromatographic (HPLC) determination of baclofen and its fluoro analogue in biological material.

Authors:  H Spahn; D Krauss; E Mutschler
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

7.  Baclofen toxicity associated with declining renal clearance after ibuprofen.

Authors:  P A Dahlin; J George
Journal:  Drug Intell Clin Pharm       Date:  1984-10

8.  Comparison of the pharmacokinetics of intravenously administered rac-baclofen and its (-)-(R)- and (+)-(S)-enantiomers in dogs.

Authors:  E W Wuis; M J Dirks; E F Termond; T B Vree; E Van der Kleijn
Journal:  Int J Clin Pharmacol Res       Date:  1989

9.  The pharmacokinetics of baclofen derived from intestinal infusion.

Authors:  G M Kochak; A Rakhit; W E Wagner; F Honc; L Waldes; R A Kershaw
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

10.  Baclofen in the elderly stroke patient its side-effects and pharmacokinetics.

Authors:  A Hulme; W J MacLennan; R T Ritchie; V A John; P A Shotton
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more
  26 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Baclofen intoxication: a "fun drug" causing deep coma and nonconvulsive status epilepticus--a case report and review of the literature.

Authors:  Guido F Weißhaar; Marc Hoemberg; Katja Bender; Ursula Bangen; Peter Herkenrath; Frank Eifinger; Markus Rothschild; Bernhard Roth; André Oberthuer
Journal:  Eur J Pediatr       Date:  2012-06-23       Impact factor: 3.183

3.  Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.

Authors:  Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2015-02-25       Impact factor: 5.250

Review 4.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

5.  Baclofen overdose treated with continuous venovenous hemofiltration.

Authors:  Didier Meulendijks; Saheed Khan; Cornelis H W Koks; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Eur J Clin Pharmacol       Date:  2015-01-09       Impact factor: 2.953

6.  Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.

Authors:  Yang He; Janice E Brunstrom-Hernandez; Liu Lin Thio; Shellie Lackey; Deborah Gaebler-Spira; Maxine M Kuroda; Elaine Stashinko; Alexander H Hoon; Jilda Vargus-Adams; Richard D Stevenson; Stephanie Lowenhaupt; John F McLaughlin; Ana Christensen; Nienke P Dosa; Maureen Butler; Aloysia Schwabe; Christina Lopez; Desiree Roge; Diane Kennedy; Ann Tilton; Linda E Krach; Andrew Lewandowski; Hongying Dai; Andrea Gaedigk; J Steven Leeder; William J Jusko
Journal:  J Pediatr       Date:  2014-03-05       Impact factor: 4.406

7.  Haemodialysis clearance of baclofen.

Authors:  Miran Brvar; Matjaz Vrtovec; Damjan Kovac; Gordana Kozelj; Tomaz Pezdir; Matjaz Bunc
Journal:  Eur J Clin Pharmacol       Date:  2007-09-02       Impact factor: 2.953

8.  Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.

Authors:  Matthew J McLaughlin; Yang He; Janice Brunstrom-Hernandez; Liu Lin Thio; Bruce C Carleton; Colin J D Ross; Andrea Gaedigk; Andrew Lewandowski; Hongying Dai; William J Jusko; J Steven Leeder
Journal:  PM R       Date:  2017-09-01       Impact factor: 2.298

9.  Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses.

Authors:  E W Wuis; M J Dirks; T B Vree; E Van der Kleijn
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

10.  Differential development of tolerance to the functional and behavioral effects of repeated baclofen treatment in rats.

Authors:  T J R Beveridge; H R Smith; L J Porrino
Journal:  Pharmacol Biochem Behav       Date:  2013-03-13       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.